Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
Date:10/21/2008

NANJING, China, Oct. 21 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 third quarter results on Thursday, November 6, 2008, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2008 third quarter results on Thursday, November 6, at 8 a.m. ET (Thursday, November 6, at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free dial-in number: +1-866-314-4483

United States toll / International dial-in number: +1-617-213-8049

China toll-free dial-in number: 10-800-130-0399

Hong Kong dial-in number: +852-3002-1672

Please ask to be connected to Simcere's Q3 2008 Earnings Call and provide the following passcode: 91351092. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com .

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1-888-286-8010

United States toll / International dial-in number: +1-617-801-6888

The passcode for replay participants is: 53343092. The telephone replay also will be archived on the "I
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
(Date:11/18/2014)... 2014 2014 Deep Research ... professional and in-depth report on Polytetrahydrofuran (PTMEG) ... including its definition, characterization, application, and industry ... exploration covers the worldwide business investigation, including ... covering macroeconomic environment & financial circumstance examination. ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... March 14 Kendle (Nasdaq: KNDL ), ... Senior Vice President and Chief Financial Officer Karl,"Buzz" ... Eleventh,Annual Global Healthcare Conference. The conference will be ... Florida, March 18-20, 2008. Kendle,s,presentation is scheduled for ...
... Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... it is scheduled to speak,at the Cowen and ... March 18, 2008, at the Marriott Copley Place, ... begin at,8:45 a.m. Eastern Time., The presentation ...
... March 14 Creighton University,law, science, medical and ... it takes to convert scientific research into new ... a competitive application and,interview process -- are enrolled ... time on Feb. 13. A three-year, $536,000 National ...
Cached Biology Technology:Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NSF Funds New Entrepreneurship Program 2
(Date:11/4/2014)... published research study examining only marketing directed at ... food restaurants has found that the majority of ... to such marketing tactics. , Authored by Arizona ... the study is the first to examine the ... exterior of fast food restaurants and its relationship ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... Los Baos, Philippines A small insect that has devastated ... over the past few yearscausing the loss of thousands of ... productionis the focus of a critical and timely conference this ... major type of rice pest that can destroy one-fifth of ...
... and Texas A & M University have discovered a ... specific tissues in animals. In studies to determine ... group previously identified a region of a smooth muscle ... of any plasmid carrying this sequence uniquely in cultured ...
... to Consultancy in Automotive, IRVINE, Calif., June 20 ... auto industry executive who has worked with,Jaguar, Audi, Volkswagen, ... The,position will be based in Irvine, Calif., and will ... responsible for managing existing,client relationships as well as developing ...
Cached Biology News:Research required urgently to control planthopper pests 2Research required urgently to control planthopper pests 3New paradigm for cell-specific gene delivery 2Len Hunt Joins Gallup Consulting Group 2
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Assay Diluent, 10 L...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Biology Products: